BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cabotegravir (Apretude) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cabotegravir (Apretude)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05986084-11050@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cabotegravir (Apretude): Phase 4 readout est. (NCT05986084)
DESCRIPTION:Cabotegravir (Apretude)\, phase 4.\nStudy: Tshireletso: Safety\
 , Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Popu
 lation in Botswana\nEstimated primary completion: 31 August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cabotegravir-apretude#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05986084
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06474364-11050@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Cabotegravir (Apretude): Phase 4 readout est. (NCT06474364)
DESCRIPTION:Cabotegravir (Apretude)\, phase 4\, HIV.\nStudy: HIV Prevention
  and Care Interventions for Youth in Uganda\nEstimated primary completion:
  31 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabo
 tegravir-apretude#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06474364
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07199335-11050@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cabotegravir (Apretude): Phase 4 readout est. (NCT07199335)
DESCRIPTION:Cabotegravir (Apretude)\, phase 4\, HIV.\nStudy: Long-acting Ca
 botegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs
 \nEstimated primary completion: December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07199335
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07346508-11050@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cabotegravir (Apretude): Phase na readout est. (NCT07346508)
DESCRIPTION:Cabotegravir (Apretude)\, phase na\, HIV.\nStudy: Project SPEED
  - Streamlined Protocol for Early Engagement and Delivery of HIV Preventio
 n With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol\nEstim
 ated primary completion: 31 December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07346508
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06134362-11050@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20290314
DTEND;VALUE=DATE:20290315
SUMMARY:Cabotegravir (Apretude): Phase 3 readout est. (NCT06134362)
DESCRIPTION:Cabotegravir (Apretude)\, phase 3\, HIV.\nStudy: Long-term Foll
 ow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophyla
 xis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Viru
 s)\nEstimated primary completion: 14 March 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06134362
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06854029-11050@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Cabotegravir (Apretude): Phase 4 readout est. (NCT06854029)
DESCRIPTION:Cabotegravir (Apretude)\, phase 4\, HIV.\nStudy: NOTRE: Optimiz
 ing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Di
 sorder Interventions in Carceral Settings\nEstimated primary completion: 1
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabot
 egravir-apretude#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06854029
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672717-11050@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Cabotegravir (Apretude): Phase 1 readout est. (NCT07672717)
DESCRIPTION:Cabotegravir (Apretude)\, phase 1\, HIV.\nStudy: Cabotegravir-H
 ormone PK/PD Interactions for HIV Prevention\nEstimated primary completion
 : December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cabo
 tegravir-apretude#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07672717
URL:https://assetmemo.bio/drug/cabotegravir-apretude#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
